CART Therapy in GUCY2C-positive Digestive Tract Tumors — CART

Malignant Neoplasms of Digestive Organs Clinical Trial

Official title:
Clinical Study on the Safety and Efficacy of CART Cells in the Treatment of Advanced GUCY2C-positive Digestive Tract Tumors

Status Completed

Clinical Trial Summary

Ict-gc is an open, single-center study to evaluate the safety and efficacy of CAR-T-targeted therapy in patients with advanced gastrointestinal tumors.

Clinical Trial Description

The primary objective of phase 1 is to evaluate the safety of CART regimens. The primary objective of phase 2 is to evaluate the efficacy of CART, as measured by objective response rate in subjects with colorectal cancer. Secondary objectives will include assessing the safety and tolerability of CART and additional efficacy endpoints. ;

Study Design

Related Conditions & MeSH terms

Malignant Neoplasms of Digestive Organs
Neoplasms

Clinical Trial Details

NCT number	NCT04652219
Study type	Interventional
Source	Zhejiang University
Contact
Status	Completed
Phase	Early Phase 1
Start date	October 10, 2020
Completion date	October 9, 2021

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02812056` - Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies	Phase 1
Completed	`NCT03210376` - Neuromuscular Blockade on Shoulder Pain of Elderly	Phase 4
Completed	`NCT03428126` - Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer	Phase 2
Not yet recruiting	`NCT04780529` - CART Therapy in Digestive System Tumors	N/A
Active, not recruiting	`NCT03435952` - Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT	Phase 1
Withdrawn	`NCT02915172` - Lenvatinib and Capecitabine in Patients With Advanced Malignancies	Phase 1
Active, not recruiting	`NCT03162627` - Selumetinib and Olaparib in Solid Tumors	Phase 1